[go: up one dir, main page]

WO2014184545A3 - Engineered fc variants - Google Patents

Engineered fc variants Download PDF

Info

Publication number
WO2014184545A3
WO2014184545A3 PCT/GB2014/051469 GB2014051469W WO2014184545A3 WO 2014184545 A3 WO2014184545 A3 WO 2014184545A3 GB 2014051469 W GB2014051469 W GB 2014051469W WO 2014184545 A3 WO2014184545 A3 WO 2014184545A3
Authority
WO
WIPO (PCT)
Prior art keywords
engineered
variants
polypeptides
antibodies
proteins
Prior art date
Application number
PCT/GB2014/051469
Other languages
French (fr)
Other versions
WO2014184545A2 (en
Inventor
Matthew David Max Crispin
Xiaojie Yu
Christopher Neil Scanlan
Original Assignee
Isis Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation Limited filed Critical Isis Innovation Limited
Publication of WO2014184545A2 publication Critical patent/WO2014184545A2/en
Publication of WO2014184545A3 publication Critical patent/WO2014184545A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to polypeptides, proteins and antibodies comprising a FcγRIIB-binding domain. The invention further relates to methods of suppressing immune cell activation or immuno-suppression, and particularly to methods of treating inflammatory and autoimmune disorders using such polypeptides, proteins and antibodies.
PCT/GB2014/051469 2013-05-14 2014-05-14 Antibodies WO2014184545A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1308658.2 2013-05-14
GB201308658A GB201308658D0 (en) 2013-05-14 2013-05-14 Antibodies

Publications (2)

Publication Number Publication Date
WO2014184545A2 WO2014184545A2 (en) 2014-11-20
WO2014184545A3 true WO2014184545A3 (en) 2015-02-19

Family

ID=48700766

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2014/051469 WO2014184545A2 (en) 2013-05-14 2014-05-14 Antibodies

Country Status (2)

Country Link
GB (1) GB201308658D0 (en)
WO (1) WO2014184545A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017007744A (en) 2014-12-23 2017-09-05 Bristol Myers Squibb Co Antibodies to tigit.
BR112017028353A2 (en) 2015-06-29 2018-09-04 The Rockfeller University cd40 antibodies with enhanced agonist activity
KR20180114223A (en) 2016-03-04 2018-10-17 더 락커펠러 유니버시티 Antibodies to CD40 with enhanced agonist activity
WO2018183520A1 (en) * 2017-03-28 2018-10-04 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
ES2923143T3 (en) 2017-05-25 2022-09-23 Bristol Myers Squibb Co Antagonistic monoclonal antibodies against CD40 and their uses
JP7284759B2 (en) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー ANTI-CD40 ANTIBODY AND USES THEREOF
CN110151987B (en) * 2018-02-11 2023-10-13 汕头大学医学院 Use of symmetrical IgG and its composition in preparing drugs for treating and preventing tumors
KR20200034584A (en) * 2018-09-21 2020-03-31 주식회사 동진쎄미켐 Novel compound for capping layer and organic electroluminescent device including the same
AR117091A1 (en) 2018-11-19 2021-07-07 Bristol Myers Squibb Co MONOCLONAL ANTIBODIES ANTAGONISTS AGAINST CD40 AND THEIR USES
WO2020207470A1 (en) 2019-04-10 2020-10-15 南开大学 Anti-cd40 antibody and use thereof
BR112022017632A2 (en) * 2020-03-05 2022-11-08 Momenta Pharmaceuticals Inc HYPERSIALYLATED IMMUNOGLOBULIN PRODUCTION METHODS
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087324A2 (en) * 2002-04-09 2003-10-23 Children's Hospital, Inc. Antibody gene transfer and recombinant aav
WO2006019447A1 (en) * 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
WO2010033736A1 (en) * 2008-09-17 2010-03-25 Xencor, Inc. Novel compositons and methods for treating ige-mediated disorders
WO2012162277A1 (en) * 2011-05-25 2012-11-29 Merck Sharp & Dohme Corp. METHOD FOR PREPARING Fc-CONTAINING POLYPEPTIDES HAVING IMPROVED PROPERTIES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US20070023129A1 (en) 2005-07-29 2007-02-01 Stieler David C Method of coupling polymeric tubing to polymeric coated metal tubing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087324A2 (en) * 2002-04-09 2003-10-23 Children's Hospital, Inc. Antibody gene transfer and recombinant aav
WO2006019447A1 (en) * 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
WO2010033736A1 (en) * 2008-09-17 2010-03-25 Xencor, Inc. Novel compositons and methods for treating ige-mediated disorders
WO2012162277A1 (en) * 2011-05-25 2012-11-29 Merck Sharp & Dohme Corp. METHOD FOR PREPARING Fc-CONTAINING POLYPEPTIDES HAVING IMPROVED PROPERTIES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIAOJIE YU ET AL: "Engineering Hydrophobic Protein-Carbohydrate Interactions to Fine-Tune Monoclonal Antibodies", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 135, no. 26, 3 July 2013 (2013-07-03), pages 9723 - 9732, XP055132222, ISSN: 0002-7863, DOI: 10.1021/ja4014375 *

Also Published As

Publication number Publication date
GB201308658D0 (en) 2013-06-26
WO2014184545A2 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
WO2014184545A3 (en) Engineered fc variants
SG10201909716RA (en) Modified j-chain
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
WO2014150877A3 (en) Anti-tau antibodies and methods of use
MX2020003260A (en) Fc-receptor binding modified asymmetric antibodies and methods of use.
HK1208476A1 (en) Anti-b7-h6 antibody, fusion proteins, and methods of using the same b7-h6
WO2014144865A3 (en) Anti-crth2 antibodies and their use
WO2014165271A3 (en) Tau immunotherapy
WO2014144960A3 (en) Fc variants
NZ703423A (en) Antibodies to tau
MX2014012978A (en) Modified antibody regions and uses thereof.
EP3107938A4 (en) Modified antigen binding polypeptide constructs and uses thereof
TN2012000366A1 (en) Anticoagulant antidotes
WO2013123432A3 (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
MX363533B (en) Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof.
WO2012131555A3 (en) Hetero-dimeric immunoglobulins
WO2014078268A8 (en) Anti-hemagglutinin antibodies and methods of use
MX343659B (en) Fc RECEPTOR BINDING PROTEINS.
HK1208810A1 (en) C-terminal and central epitope a-beta antibodies c a-
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof
WO2013106273A3 (en) Peptides and methods of using same
TN2013000388A1 (en) Anticoagulant antidotes
EP3095796A4 (en) Anti-human probdnf monoclonal antibody, and uses thereof in pains
PH12016500826B1 (en) Anti-ccl17 antibodies
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14727228

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 17.02.2016)

122 Ep: pct application non-entry in european phase

Ref document number: 14727228

Country of ref document: EP

Kind code of ref document: A2